Global top pharmaceutical companies by oncology market share 2017 and 2024

Top 10 pharmaceutical companies based on global oncology market share in 2017 and 2024

Global top pharmaceutical companies by oncology market share 2017 and 2024 Swiss -based company Roche was the global leader based on oncology market share in 2017 and is forecasted to maintain this position until 2024. However, it is expected that the market share will decrease dramatically from the current 26 percent to under 12 percent by 2024. The main reason for this development is that competitors like Celgene, Bristol Myers-Squibb, and Johnson and Johnson will dominate with their key oncology products by that year. Additionally, several of Roche’s blockbuster oncologic drugs will face sales erosion due to biosimilar competition.
Oncology market overview

The oncology market is expected to increase with a compound annual growth rate of twelve percent worldwide between 2017 and 2024. Traditionally, oncology is one of the three leading therapy classes worldwide by spending, accompanied by pain medication and antidiabetics. Around 45 percent of the global market is generated in the United States alone, making it the world’s top national oncology market. Another 20 percent of the market remains in the leading five EU- countries. At this moment, the three best-selling cancer drugs worldwide are Celgene’s Revlimid and Roche’s Rituxan and Herceptin.

The rise of immune-oncology

The aim in immunotherapy is the same as with immunizations (vaccinations) – to use the human body’s inherent defenses to fight the disease. Immune-oncology is a type of immunotherapy that specifically targets cancer cells. The great advantage of immune-oncology is the targeted approach, which leaves the rest of the body unharmed compared to traditional treatments. The fight against the many types of cancer is still one of the great challenges in modern medicine and personalized treatments already show huge potential. The global cancer immunotherapy market is projected to reach 117 billion U.S. dollars by 2022.
Show more

Top 10 pharmaceutical companies based on global oncology market share in 2017 and 2024

Loading statistic...
Expand statistic
20172024*
Roche26.4%11.9%
Celgene11.2%8%
Bristol-Myers Squibb8.2%6.3%
Johnson & Johnson5.9%6.1%
Pfizer5.6%6%
AstraZeneca3.9%5.9%
Merck & Co4%5.7%
Novartis7.6%4.2%
AbbVie3%3.6%
Astellas Pharma2.7%2.5%
20172024*
Roche26.4%11.9%
Celgene11.2%8%
Bristol-Myers Squibb8.2%6.3%
Johnson & Johnson5.9%6.1%
Pfizer5.6%6%
AstraZeneca3.9%5.9%
Merck & Co4%5.7%
Novartis7.6%4.2%
AbbVie3%3.6%
Astellas Pharma2.7%2.5%
Download Settings Share
Download started
Please be patient - this may take a moment
Swiss -based company Roche was the global leader based on oncology market share in 2017 and is forecasted to maintain this position until 2024. However, it is expected that the market share will decrease dramatically from the current 26 percent to under 12 percent by 2024. The main reason for this development is that competitors like Celgene, Bristol Myers-Squibb, and Johnson and Johnson will dominate with their key oncology products by that year. Additionally, several of Roche’s blockbuster oncologic drugs will face sales erosion due to biosimilar competition.
Oncology market overview

The oncology market is expected to increase with a compound annual growth rate of twelve percent worldwide between 2017 and 2024. Traditionally, oncology is one of the three leading therapy classes worldwide by spending, accompanied by pain medication and antidiabetics. Around 45 percent of the global market is generated in the United States alone, making it the world’s top national oncology market. Another 20 percent of the market remains in the leading five EU- countries. At this moment, the three best-selling cancer drugs worldwide are Celgene’s Revlimid and Roche’s Rituxan and Herceptin.

The rise of immune-oncology

The aim in immunotherapy is the same as with immunizations (vaccinations) – to use the human body’s inherent defenses to fight the disease. Immune-oncology is a type of immunotherapy that specifically targets cancer cells. The great advantage of immune-oncology is the targeted approach, which leaves the rest of the body unharmed compared to traditional treatments. The fight against the many types of cancer is still one of the great challenges in modern medicine and personalized treatments already show huge potential. The global cancer immunotherapy market is projected to reach 117 billion U.S. dollars by 2022.
Show more
Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Related Studies: Available to Download in PDF or PPTX Format
Oncology
Oncology

All Information
in one Presentation

Oncology

Everything On "Oncology" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Oncology"
  • Cancer facts
  • Oncology market
  • Companies
  • Cancer drugs
  • Research and development
  • Immuno-oncology
  • Treatment types
  • Physicians and patients
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.